DKSH eyes €2 billion acquisition to dominate pharma distribution
DKSH Holding (OTCPK:DKSHF), a Swiss company with a distribution and marketing platform valued at approximately 1 billion Swiss francs, is considering the acquisition of Swiss pharmaceutical distributor Swixx Biopharma. Swixx Biopharma, which specializes in navigating distribution in smaller and more regulated markets across 44 countries, generated €900 million in revenue last year.
Swixx Biopharma is expected to fetch between €1.5 billion to €2 billion ($1.7 billion to $2.2 billion) in a potential sale. Besides DKSH Holding, other companies evaluating bids include private-equity firms SK Capital Partners and Lone Star. Additionally, HBM Healthcare Investments has been named as a potential bidder alongside these companies. The acquisition would likely strengthen DKSH Holding's position in the pharmaceutical distribution sector, given Swixx Biopharma's extensive global reach and expertise in navigating complex markets.
The potential acquisition of Swixx Biopharma by DKSH Holding is part of a broader trend of consolidation in the pharmaceutical distribution industry. As the process unfolds, industry watchers will be keen to see which company ultimately secures the deal and how the combined entity will shape the competitive landscape.
